AGY — Allergy Therapeutics Share News
0.000.00%
- £266.92m
- £263.25m
- £59.59m
- 14
- 4
- 100
- 30
REG - Allergy Therapeutics - Amendment to existing Facility Agreement
AnnouncementREG - Allergy Therapeutics - Annual Report and Accounts Delayed
AnnouncementREG - Allergy Therapeutics - PDMR dealing and Total Voting Rights
AnnouncementREG - Allergy Therapeutics - G306 Phase III trial meets key endpoints
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Total Voting Rights
AnnouncementREG - Allergy Therapeutics - Holding(s) in Company
AnnouncementREG - Allergy Therapeutics - G306 Grass Phase III trial meets primary endpoint
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Panmure Gordon (UK). Allergy Therapeutics - Form 8.5 (EPT/RI)
AnnouncementREG - Allergy Therapeutics - Director/PCA Dealing
AnnouncementREG - Allergy Therapeutics - Holding(s) in Company
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - ZQ Capital Limited Allergy Therapeutics - Offer Closure
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Allergy Therapeutics - Exercise of Options and Total Voting Rights
AnnouncementREG - Cavendish Securities Allergy Therapeutics - Form 8.5 (EPT/NON-RI)
AnnouncementREG - Panmure Gordon (UK). Allergy Therapeutics - Form 8.5 (EPT/RI)
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement